Collaborations & Alliances

Array, BMS in Opdivo Clinical Combo Alliance

To investigate Array's binimetinib in combination with BMS' Opdivo and Opdivo + Yervoy regimen in colorectal cancer

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Array BioPharma and Bristol-Myers Squibb Co. have entered into a clinical research collaboration to investigate the safety, tolerability and efficacy of Array’s investigational MEK inhibitor, binimetinib in combination with BMS’ Opdivo (nivolumab) and Opdivo + Yervoy (ipilimumab) regimen as a potential treatment for metastatic colorectal cancer in patients with microsatellite stable tumors.   The Phase 1/2 study is expected to establish recommended dose regimens for further study a...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters